Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.
Following the Pfizer-Biohaven blueprint, could other licensing deals turn into buyouts?
Trading well below cash hasn’t stopped Cullinan from extracting more from Otsuka, when a low-ball buyout might have been on the cards.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
After several cancer failures Celldex tries its hand at autoimmune disease, and the market likes it.